Single centre experience on the use of low dose subcutaneous cytarabine in treatment of patients with high-risk myelodysplastic syndrome and acute myeloid leukaemia

被引：0
|
作者：
Schneider, T. [1 ]
Narayanan, S. [1 ]
机构：
[1] Univ Hosp Southampton NHS Fdn Trust, Dept Haematol, Southampton, Hants, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 157卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
161
引用
收藏
页码：63 / 63
页数：1
相关论文
共 50 条
  • [41] Outcomes of patients with high-risk acute myeloid leukaemia relapsed after allogeneic stem cell transplantation. Single-centre experience
    Steinerova, K.
    Koza, V.
    Jindra, P.
    Karas, M.
    Svoboda, T.
    Lysak, D.
    Vokurka, S.
    Vozobulova, V.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S116 - S116
  • [42] Low dose of homoharringtonine and cytarabine-based priming induction regimens for patients with de novo acute myeloid leukemia and high-risk myelodysplastic syndrome aged over 70 years
    Wang, Fang
    Xu, Wenyan
    Liu, Li
    Ren, Xiuhong
    Liu, Pingping
    Zheng, Li
    Zhang, Hao
    Zhang, Songsong
    Xu, Yaru
    Guo, Zhenxing
    HEMATOLOGY, 2021, 26 (01) : 1040 - 1045
  • [43] TREATMENT OUTCOME IN UNSELECTED PATIENTS WITH ACUTE MYELOID LEUKAEMIA: THE SINGLE CENTRE EXPERIENCE OF THE WILHELMINEN HOSPITAL
    Schreder, M. S.
    Strasser-Weippl, K.
    Zojer, N.
    Brigitte, B.
    Meran, J. G.
    Ludwig, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 558 - 558
  • [44] Sequential conditioning in high-risk leukaemia: a single-centre experience in 116 patients
    Kobbe, G.
    Kondakci, M.
    Czibere, A.
    Bruns, I.
    Balleisen, S.
    Fenk, R.
    Distelmeier, L.
    Graef, T.
    Germing, U.
    Haas, R.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S87 - S87
  • [45] Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia
    Xueya Zhang
    Xizhe Guo
    Annals of Hematology, 2019, 98 : 2223 - 2225
  • [46] LOW-DOSES OF CYTARABINE IN THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID-LEUKEMIA
    MUFTI, GJ
    OSCIER, DG
    HAMBLIN, TJ
    BELL, AJ
    NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (26): : 1653 - 1654
  • [47] Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia
    Zhang, Xueya
    Guo, Xizhe
    ANNALS OF HEMATOLOGY, 2019, 98 (09) : 2223 - 2225
  • [48] Allogeneic stem cell transplantation in patients with myelodysplastic syndromes/secondary acute myeloid leukaemia: A single-centre experience
    Boehm, A.
    Sperr, W.
    Valent, P.
    Greinix, H. T.
    Kalhs, P.
    Hauser, H.
    Rabitsch, W.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S436 - S436
  • [49] Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome
    Lee, ST
    Jang, JH
    Suh, HC
    Hahn, JS
    Ko, YW
    Min, YH
    AMERICAN JOURNAL OF HEMATOLOGY, 2001, 68 (04) : 237 - 245
  • [50] Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience
    Bashir, Yasir
    Geelani, Sajjad
    Bashir, Nusrat
    Mir, Shabeer A.
    Mushtaq, Mosin
    Jan, M. Aleem
    Rasool, Javid
    SOUTH ASIAN JOURNAL OF CANCER, 2015, 4 (01) : 4 - 6
12345